Drug intelligence / Profile preview

cmAb17-1A

Development stage: Unknown
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

cmAb17-1A is a chimeric monoclonal antibody that targets the tumor-associated antigen GA733-2, which is also known as EpCAM (epithelial cell adhesion molecule). It consists of mouse variable regions and human IgG1 constant regions. The drug was developed for use in cancer immunotherapy, specifically in patients with advanced colorectal carcinoma. Its mechanism involves binding to the GA733-2 antigen on tumor cells, potentially inducing an immune response against these cells. Clinical studies have shown that treatment with cmAb17-1A can induce anti-tumor immune responses, including the development of anti-idiotypic and anti–anti-idiotypic antibodies[2].

Other names: chimeric monoclonal antibody 17-1A

Targets

EPCAM (Epithelial cell adhesion molecule)

Beyond the preview

Go deeper on cmAb17-1A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cmAb17-1A.

Explore the full profile